Emily Collins, Nutrition Researcher (Supplements & Superfoods)

You may have encountered SS-31 in a longevity blog, a biohacking forum, or — if you searched long enough — listed in the catalog of a grey-market peptide vendor. The pitch is usually some version of: "mitochondrial optimizer, clinically tested, fights aging at the cellular level." The reasonable question is whether any of that reflects

Sermorelin is a strange case. It was once FDA-approved — sold as Geref, studied in multicenter pediatric trials, used in endocrine clinics for more than a decade. The manufacturer voluntarily pulled it from the market in 2008 for commercial reasons, not safety concerns. And now it lives almost entirely as a compounded peptide marketed by

If you take mealtime insulin and still struggle with blood sugar spikes after meals, you may have been told there is nothing else left to try. Is that actually true? And if another FDA-approved injectable exists for exactly that situation, why has almost no one heard of it? Pramlintide — sold as Symlin — has

If you have heard that Ozempic owes its existence to a lizard, the honest answer is yes — but the full story runs through a Bronx veterans' hospital, three decades of skepticism, and a regulatory landscape that looked very different before anyone had heard of semaglutide. Exenatide was the first GLP-1 receptor agonist to reach

If you are reading about Trulicity because someone in your life takes it for weight loss, the first thing worth knowing is that dulaglutide does not have an FDA-approved weight-management indication. It never has. The confusion is understandable — Trulicity belongs to the same GLP-1 receptor agonist drug class as Ozempic and Wegovy, and the